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Abstract 
 
 
Early and accurate detection of tumors, like the development of targeted treatments, is a major 
field of research in oncology. The generation of specific vectors, capable of transporting a 
drug or a contrast agent to the primary tumor site as well as to the remote (micro-) metastasis 
would be an asset for early diagnosis and cancer therapy. Our goal was to develop new 
treatments based on the use of tumor-targeted delivery of large biomolecules (DNA, siRNA, 
peptides, or nanoparticles), able to induce apoptosis while dodging the specific mechanisms 
developed by tumor cells to resist this programmed cell death. Nonetheless, the insufficient 
effectiveness of the vectorization systems is still a crucial issue. In this context, we generated 
new targeting vectors for drug and biomolecules delivery and developed several optical 
imaging systems for the follow-up and evaluation of these vectorization systems in live mice. 
Based on our recent work, we present a brief overview of how noninvasive optical imaging in 
small animals can accelerate the development of targeted therapeutics in oncology. 
1. Introduction 
 
Cancer is a major public health problem. It is the leading cause of death in the world, before 
cardiovascular diseases. Significant progress has been made in the last decade, but the 
improvement of diagnosis, with early and accurate detection of tumors, as well as the 
development of innovative targeted therapies continue to be researched intensely (Cho et al., 
2008; Clift et al., 2008; Owens and Peppas, 2006; Pierce et al., 2008). 
The generation of specific vectors, capable of addressing a toxic drug and/or a contrast agent 
to the primary tumor site and remote metastases would therefore be a fundamental asset for 
early diagnosis and cancer therapy. In collaboration with chemists and physicists, we 
developed targeted delivery vectors as well as optical imaging systems for tracking them once 
they have been injected in tumor-bearing mice. 
Optical imaging was chosen among the different imaging methods currently available because 
optics can be applied to a wide range of applications (from cells to animals) as well as to 
humans (Anandasabapathy, 2008; Tromberg et al., 2005). Indeed, optical imaging is a 
noninvasive method that can be used to follow the molecules in real time at good spatial (the 
nanometer to millimeter range) and temporal resolution (microseconds to a few minutes), 
with high sensitivity (the femto- to picomolar range), and from the whole-body to the 
subcellular scale (Kumar and Richards-Kortum, 2006). 
However, the use of molecular imaging, especially fluorescence imaging in live animal 
models is limited by the poor transmission of visible light through biological tissues and by 
the autofluorescence of the tissues because of the presence of natural fluorophores. However, 
longer wavelengths can be used in a near-infrared (NIR) optical window (650-900 nm). In 
this spectrum, the problems caused by absorption and autofluorescence are reduced, but 
others are amplified because of the diffusion and scattering of these photons in biological 
tissues (Ripoll et al., 2005). In addition, the recent description of increasing amounts of 
organic or inorganic NIR fluorochromes has also contributed to the development of optical 
imaging methods for the investigation of deep tissues (Weissleder, 2001; Weissleder and 
Ntziachristos, 2003). This type of fluorochrome can be used for labeling molecules of interest 
and will significantly accelerate the preclinical study of various kinds of therapeutic, 
diagnostic, or ultimately theranostic tools (multifunctional nano-carriers with both functions). 
Optics can also be used to detect subtle spectral variations in biological tissues and thus will 
help discriminate between normal and pathologic tissues. For example, diffuse NIR imaging 
was applied for the detection of tumors and the biological evaluation of the response to 
neoadjuvant chemotherapy in patients with breast cancer (Tromberg et al, 2005). 
The aim of this article is to illustrate how different optical fluorescence imaging systems can 
be used to improve the study of macromolecules from the cellular to the small animal scales. 
This will be exemplified for two kinds of drug carriers: targeted peptides and nanoparticles, 
visualized with several homemade 2D and 3D optical imaging systems. 
The target peptide we developed, called RAFT(c[-RGDfK-])4 (RAFT-RGD), is a 10-Å large 
cyclic peptide able to target the transmembrane protein integrin MvM3. This protein is 
overexpressed on neoformed endothelial cells, such as those forming the tumor blood vessels, 
where it plays a role in cellular adhesion, proliferation, and migration (Rupp et al., 2004; 
Stupack and Cheresh, 2002). Furthermore, integrin MvM3 is also frequently overexpressed on 
several tumor cells themselves, as observed in lung cancers (Chen et al., 2005; Sato et al., 
2001), melanomas (Gehlsen et al., 1992; Seftor et al., 1992), brain tumors (Gladson and 
Cheresh, 1991) and breast cancers (Rolli et al., 2003). Coupled to an optical or nuclear 
imaging agent, RAFT-RGD can detect metastatic tumors engrafted in mice (Ahmadi et al., 
2008; Garanger et al., 2007; Garanger et al., 2005; Jin et al., 2007; Jin et al., 2006; Sancey et 
al., 2007) and deliver a toxic (KLAKLAK)2 (KLA) peptide (Foillard et al., 2008). We will 
illustrate the interest of functional imaging using optics to follow the subcellular release of 
these peptides. 
We have also been involved in the development of various multifunctional nanoparticles 
(NPs). NPs are very well suited for imaging and/or therapy because of their small size, which 
is sufficiently large, however, to allow the multiplexing and fine-tuning of several biological 
functions in a single object. Extensive studies focused on liposomes or polymeric particles 
have demonstrated how modifying the surface of the particles by adding shielding polymers 
such as polyethylene glycol (PEG) improve their pharmacodynamic properties (Alexis et al., 
2008; Lukyanov and Torchilin, 2004; Owens and Peppas, 2006). The derivatization by PEG 
chains limits the uptake of the particles by Kupfer cells, macrophages, or B cells and their 
opsonization by various blood proteins (Alexis et al., 2008, Clift et al., 2008). In this study, 
we will also illustrate the advantage of using optical systems to rapidly evaluate such 
modifications. 
 
2. Material and methods 
 
2.1. RGD-Peptides Synthesis and Fluorescent Labeling 
Compounds were synthetized according to previously reported procedures (Boturyn et al., 
2004; Foillard et al., 2008): the chemical structures are presented in Fig. 1. Briefly, RAFT is a 
cyclic decapeptide (c [-Lys(Boc)-Lys(Alloc)-Lys(Boc)-Pro-Gly-Lys(Boc)-Lys(Alloc)- 
Lys(Boc)-Pro-Gly-]) with two orthogonally addressable domains pointing to either side of the 
cyclopeptide backbone. On the upper side, four copies of the c[-RGDfK-] peptide were 
grafted via an oxime bond (R1-O-N=C-R2) for recognition of the integrin MvM3. On the other 
side of the RAFT, a peptidic sequence (KLAKLAK)2-NH2 (KLA) was grafted via a disulfide 
bridge and a short linker on the lysine chain (c [-KKKPGKAKPG-]) (Garanger et al., 2005). 
From both parts of this disulfide bridge, a quencher (QSH21®) or a Cy3 mono-NHS 
(Nhydroxysuccinimide) ester was added on the first cysteine and a Cy5 mono-NHS-ester (all 
from Amersham Biosciences, Uppsala, Sweden) was added on the second cysteine, as 
described in Fig. 1. As a negative control probe, RAFT(c[-RβADfK-])4 (RAFT-RAD) was 
also synthesized in a similar way. 
 
2.2. Nanoparticles 
The nanoparticles (diameter M 15 nm) were as described previously (Bridot et al., 2007). They 
are made up of a metallic heart (Gadolinium oxide) embedded in a polysiloxane shell (Fig. 2). 
This shell, containing fluorescent dyes (Cy5, Amersham Biosciences) for imaging, is coated 
with polyethylene-glycol chains (PEG) to optimize their in vivo biodistribution. PEG can be 
functionalized with biological ligands to target tumor cells (Bridot et al., 2007). 
 
2.3. Cell Lines and Culture Conditions 
HEK293(M3), stable transfectants of human M3 from the human embryonic kidney cell line 
(kindly provided by J-F. Gourvest, Aventis, France), were cultured as described in Jin et al. 
(2007) in DMEM supplemented with 1% glutamine, 10% fetal bovine serum (FBS), 50 
units/ml penicillin, 50 Mg/ml streptomycin, and 700 Mg/ml Geneticin (G418 sulfate, Gibco, 
Paisley, UK). IGROV-1, human ovarian carcinoma cells, TS/A-pc, mice mammary carcinoma 
cells, and TS/A-pc-pGL3 subclone were cultured in RPMI 1640 supplemented with 1% 
glutamine, 10% fetal bovine serum (FBS), 25 nM M-mercaptoethanol, 50 units/ml penicillin, 
and 50 Mg/ml streptomycin. Stable transfections of TS/A-pc (pGL3) cells were performed 
using Jet-PEI (Polyplus-transfection, Illkirch, France) with a 4:1 ratio of pCMV-luc and 
pcDNA3 plasmids, followed by G418 (Invitrogen, Cergy Pontoise, France) selection and 
cloning of positive cells. All cell lines were cultured at 37°C in a humidified 95% air / 5% 
CO2 atmosphere. All the cells used here are integrin MvM3-positive (Jin et al., 2007; Jin et al., 
2006; Sancey et al., 2007). 
 
2.4. FRET experiment 
HEK293(M3) cells were grown as described. Fresh warm DMEM without red phenol 
(Invitrogen, Cergy Pontoise, France) was added to the cells previously stained with 5 MM 
Hoechst (Sigma Aldrich, St Quentin Fallavier, France) for 10 minutes. Then, 1 MM of 
RAFTRGD-X1 was added to the medium. Confocal microscopy was performed on the Axiovert 
200 LSM510 LNO Meta microscope (Carl Zeiss, Jena, Germany) using a 40x water immersion 
objective. The FRET signal was obtained after excitation at 543 nm and recovered at 651-716 
nm. The Cy3 and Cy5 spectral bleed-through were subtracted from the FRET images. 
 
2.5. Colocalization studies 
Cells were cultured in four-well Lab-Tek I chambered coverglass (Thermo Fisher, Illkirch, 
France) in the appropriate medium and kept at 37°C. The medium was removed and RAFTRGD- 
X2 was added at 2 MM for 1 h in DMEM without FBS and red phenol. Then, 100 nM 
mito-tracker red (M7512, Invitrogen, Cergy Pontoise, France) was added to the cell medium 
for 10 minutes together with 5 MM Hoechst. Cells were carefully rinsed and the medium was 
replaced for several hours. The cells were observed through confocal microscopy as 
previously described at 37°C, 5% CO2. Confocal slices were 0.5 or 1 Mm deep. Images (8-bit 
color) were treated with ImageJ software 1.37v (NIH, Bethesda, MD, USA). 
 
2.6. In vivo fluorescence imaging 
2.6.1. Fluorescence Reflectance Imaging (2D-FRI) 
Female NMRI nude mice (6–8 weeks old, Janvier, Le Genest-Saint-Isle, France) were 
injected subcutaneously with human HEK293(M3) cells (2°—107 cells per mouse). After tumor 
growth (M6 weeks), anesthetized mice (isoflurane/oxygen 3.5/4% for induction and 1.5/2% 
thereafter, CSP, Cournon, France) were injected intravenously with 200 ML of nanoparticle 
suspension (50 MM of dye). Depending on the fluorescent dye used, mice were illuminated by 
633- or 660-nm light-emitting diodes equipped with interference filters. Fluorescence images 
as well as black and white pictures were acquired by a back-thinned CCD camera at –80°C 
(ORCAII-BT-512G, Hamamatsu, Massy, France) (Jin et al., 2007; Jin et al., 2006; Josserand 
et al., 2007) fit with a colored glass long-pass RG 665 filter (Melles Griot, Voisins Le 
Bretonneaux, France) or the high-pass RG 9 filter (Schott, Clichy, France). At the end of the 
experiment, mice were euthanized to quantify the biodistribution in the different organs. 
2.6.2. Fluorescence tomography with fDOT 3D imaging system 
Female NMRI nude mice (6–8 weeks old, Janvier) were injected with 5.105 TS/A-pc-pGL3 
cells, intraperitoneally. After tumor growth (M7 days), anesthetized mice were injected 
intravenously with RAFT-RGD-Alexa700 (200 Ml at 50 MM of dye). Three hours after 
injection, the anesthetized mouse was put in the dark chamber and was lightly constrained by 
a glass plate. The imaging setup consists of a laser source (690 nm, 26 mW, 
Powertechnology, St Nom La Bretche, France) and a CCD camera (ORCA ER, Hamamatsu) 
fit with a colored glass high-pass RG 9 filter (Schott). The 3D map of fluorescence in the 
mice was computed by means of an ART-based reconstruction algorithm described 
previously (Herve et al., 2007). After the tomographic acquisition, a FRI as well as a black 
and white picture were acquired (Koenig et al., 2008; Da Silva et al., 2007). 
2.6.3. Bioluminescence Imaging 
Five minutes after luciferin (Promega, Charbonnières, France) intraperitoneal injection (150 
µg/g), the mice were anesthetized and bioluminescence images as well as black and white 
pictures were acquired using a back-thinned CCD camera at -80°C (ORCAII-BT-512G, 
Hamamatsu). 
2.6.4. Fluobeam 
The mice bearing TS/A-pc subcutaneous tumor were injected twice intradermically, close to 
the tumor with 5+5 ML of nanoparticles (500 MM of dye). Mice were imaged with the 
Fluobeam (Fluoptics, Grenoble, France) 15 min, 1 h and 3 h after injection. The optical 
system consists of a 690-nm laser and a pixelfly camera fitted with a high-pass RG 9 filter 
(Schott). 
 
3. Results 
 
3.1. Optical imaging of drug internalization 
In our previous work, we studied the in vivo optical imaging of RAFT-RGD-Cy5-SS-Q in 
nude mice bearing subcutaneous tumors (Jin et al., 2007). Because of the presence of a 
quencher, no fluorescence can be detected (0.5 ± 0.1% of the quantum yield efficiency as 
compared with the similar molecule without a quencher). This molecule is therefore nearly 
completely devoid of background fluorescence before the disulfide bridge is disrupted. This 
provides an excellent SNR (signal-to-noise ratio), which is a major asset in microscopy as 
well as in whole-body imaging. After intravenous administration of 10 nmol of RAFT-RGDCy5- 
SS-Q, good tumor contrasts were observed from 3 to 24 h after injection (see 
supplementary data S1). The kidneys were also visualized. Tumor samples obtained at 3 h 
showed that RAFT-RGD-Cy5-SS-Q was actively internalized by tumor cells and produced a 
much stronger fluorescence signal in tumor cells or in the stroma than RAFT-RGD-Cy5. This 
study also suggested that RAFT-RGD-Cy5-SS-Q bound to endothelial cells. 
To demonstrate that RAFT-RGD could also target deep metastasis, similar studies were 
conducted in which RAFT-RGD-Alexa700 was intravenously injected in mice bearing 
intraperitoneal, luciferase-positive breast cancer nodules (obtained after intraperitoneal 
injection of TS/A-pc-pGL3 cells). Bioluminescence imaging was used to visualize scattered 
metastasis in the peritoneal cavity. Three hours after intravenous injection of RAFT-
RGDAlexa700, 
the binding on the tumor nodules was confirmed by 2D-FRI. This was more 
precisely evaluated using the fDOT system, as shown in Fig. 3. As expected, the metastases 
were not detectable using the negative control molecule RAFT-RAD-Alexa700, which do not 
bind the integrin. 
The RAFT-RGD molecule is thus capable of targeting the cell surface receptor and inducing 
an active internalization in clathrin-coated vesicles (Sancey et al., 2009). To demonstrate that 
the RAFT-RGD vector can deliver an active toxic peptide in the appropriated subcellular 
compartment, we synthesized various “smart” molecules containing internally quenched 
FRET probes surrounding a cleavable disulfide link. In the first molecule, the FRET pair was 
made of Cy3 and Cy5. In the second molecule, Cy3 was replaced with a fluorescence 
quencher QSY21® as shown previously. In both cases, the disulfide bridge can be cleaved 
after reduction, which occurs during the internalization process. The use of Cy3 instead of  
QSY21®allowed us to simultaneously track each molecule separated after disruption of the  
disulfide bridge. Cy3 will stay attached to the RAFT-delivery vector while Cy5 will stay with  
the drug (KLA) (Fig. 1). This KLA peptide is toxic only when in contact with the  
mitochondria. It is thus necessary for the delivery system to release it in an active form into  
the cytoplasm of the cell after endocytosis. Only then can KLA reach the mitochondrion and  
destabilize it, leading to cell apoptosis.  
Using RAFT-RGD-X1, we followed the targeting and release of KLA on MvM3-expressing  
cells. As demonstrated in Fig. 4, the pseudo-colored “green” signal obtained by the Cy3  
linked to the RAFT-RGD part was mainly localized at cell junctions but was also found in  
small vesicles, as previously described for RAFT-RGD alone (Sancey et al., 2009). Most of  
the KLA, pseudo-colored in “red” was in the close vicinity of the vector RAFT-RGD or  
detached into the medium near the cell membranes. During the first half-hour, the FRET  
signal was weak, principally found at cell junctions and in some large speckles (upper panels).  
A weak FRET signal is the expected signature obtained when the two dyes are separated after  
degradation of the disulfide bridge during internalization. After 2 h, KLA was mostly  
internalized but a large amount was still linked to the RAFT-RGDvector: a positive FRET  
signal was found in subcellular organelles such as the nucleus. Usually, RAFT-RGD stayed  
onthe cell membrane or was internalized in small clathrin-coated vesicles, but it was never  
observed in the nucleus (Sancey et al., 2009). This suggests that after partial release of the  
KLA toxic peptide, the nuclear membrane may be more permeable or that addition of KLA  
onto the RAFT-RGD could provide an NLS-like property to the molecule. FRET intensity  
was stronger at T=2 h than at T=30 min butthe Cy3 signal decreased during the same period:  
this indicated that the release of the KLA decreased with time, while the accumulation of the  
intact molecule was still ongoing. 
 
3.2. Drug release  
Drug release could be observed with the RAFT-RGD-X2 (Fig. 5). Depending on the cell type,  
the time of release varied, but in three different cell types, the red signal resulting from KLA  
release was observed first in small vesicles (Fig. 5A) and then around the mitochondria (Fig.  
5B) and labeled with the mito-tracker (green). This experiment demonstrated the efficiency of  
RAFT-RGD to carry and deliver this drug into three different cell types.  
 
3.3. Optical imaging for in vivo study of the biodistribution of nanoparticles  
Whole-body 2D-FRI can be used to compare the distribution of various surface modified  
nanoparticles 24 h after intravenous injection (Fig. 6). As demonstrated in Fig. 6 (A) and (C),  
these nanoparticles present distinct biodistributions (see supplementary data S2 and S3). In  
one case (Fig. 6A), the biodistribution seemed to be homogenous with a predominant hepatic  
elimination route. In the second case (Fig. 6C), the kidneys were highly fluorescent. Semi-  
quantification of fluorescence intensities of the corresponding isolated organs (Fig. 6B and D)  
was correlated with whole-body noninvasive imaging.  
Biodistribution quantification estimated the circulation timesin mice as well as the routes and  
time of elimination. In the first case (Fig. 6 A-B), we observed a long-lasting hepatic  
fluorescence signal 24 h after injection. Indeed, the massive accumulation of fluorescence in  
the liver and the significant level of fluorescence in the intestine indicated that these  
nanoparticles were probably degraded and excreted through feces. This elimination mode is  
slower than the urinary route, increasing the circulation time of the compound in the mouse,  
thus favoring specific targeting or passive uptake. In the second case presented (Fig. 6 C-D), 
nanoparticles freely circulated in the blood and were quickly cleared from the body through  
the kidneys; no fluorescence was detected except in this organ. It is therefore likely that these  
nanoparticles were degraded and the fluorescence released and eliminated through the urinary  
route. The integrity of the nanoparticles in the different compartments is difficult to control.  
To address this problem, we are currently working on the introduction of a FRET system  
instead of a single dye. This should help determine whether the particle is still intact at the  
end.  
Moreover, whole-body scans and quantifications allowed us to evaluate the tumoral uptake.  
For one of the two nanoparticles (Fig. 6 A-B), we observed a weak accumulation in the tumor  
due to passive and nonspecific targeting.  
As demonstrated by Frangioni and Mawad's teams (Kim et al., 2004; Sevick-Muraca et al.,  
2008), such nanoparticles have the capacity to accumulate passively in draining lymph nodes.  
This is an interesting application since it may help identify draining lymph nodes associated  
with tumors. We therefore injected untargeted nanoparticles in two peri-tumoral locations  
(pink dots) and used the Fluobeam imaging system to follow the distribution of the  
nanoparticles in real time, as shown in Fig. 7, 15 min, 1 h and 3 h after injection. As observed  
after 3 h, two lymph nodes were identified draining directly the subcutaneous tumor. The  
advantage of using the Fluobeam instead of the conventional 2D-FRI system is its ability to  
function under surgical white light, allowing us to detect and remove such draining lymph  
node by optical-guided surgery (see supplementary data S4). This could be done as well in  
large animals (pigs, goat…) because the Fluobeam does not require the introduction of the  
animal in a black box, oppositely to all other conventional fluorescent imaging systems.  
 
4. Discussion 
In this study, we illustrated how optical imaging can help in the development of targeted  
therapeutics in oncology. This method allows us to noninvasively follow the fate of a  
molecule and its functional activation on a very broad scale. Indeed, using a fluorescent tag,  
the distribution of the desired molecule can be followed from the subcellular level up to the  
whole-body level (Pierce et al., 2008).  
For cell targeting and drug release, we used a synthetic peptidic RAFT-RGD vector targeting  
the MvM3integrin. Combined with different fluorescent or smart-FRET probes, we studied its  
efficiency in delivering and releasing a toxic peptide, normally unable to cross the cell  
membrane on its own.  
The FRET experiment demonstrated a rapid release of the drug after disulfide bridge rupture  
occurring after its internalization mediated by the RAFT-RGD vector in small endocytic and  
acidic vesicles (Sancey et al., 2009). After 2 h, the drug perforated many organelles, leading  
to cell death and allowing the compound to penetrate the nucleus. In this analysis, the  
different pictures were obtained after 543-or 633-nm laser excitations, for the Cy3 and FRET  
or Cy5 channel, respectively. Furthermore, the intensity of the 543-nm laser differed between  
Cy3 and FRET analysis. The use of different lasers and intensities prevented us from  
comparing the fluorescence intensities of the different emission channels. Here, two  
phenomena were observed: RAFT-RGD-X1 accumulation and KLA release. As we could not  
quantify each phenomenon separately, the amount of drug released could not be quantified in  
this experiment.  
The RAFT-RGD-X2 was constructed to follow the release of the drug and its intracellular  
trafficking. The time course of drug release varied with the cell type. In the three different cell  
types, red vesicles first appeared before accumulation in the mitochondrion. Since small  
quantities of RAFT-RGD-X2 in solution (2 MM) were used, we assumed that only a small  
quantity of the drug combined with the Cy5 was internalized with the vector RAFT-RGD, 
released into small vesicles, and escaped this organelle. This small proportion of released  
drug reached its target, as demonstrated by its colocalization with the mito-tracker probe. This  
proportion was sufficient to induce substantial cell damage representative of cell death: as  
demonstrated in Fig. 4, this concentration induced perforations of the nuclear membrane,  
leading to the diffusion of the vector and its drug into this organelle. Furthermore, the KLA  
also perforated the mitochondrial membranesdisturbing their polarization and leading to cell  
death (data not shown).  
Such functional characteristics could effectively be investigated with optical imaging  
techniques. This method gives access to in celluloassociation/dissociation of compounds  
using appropriate techniques (FRET, FRAP, etc) (Rajwa, 2005). At the animal level, optical  
imaging also allowed us to determine specific organ accumulation, particularly in tumors, and  
gave functional information such as tumoral growth and vascularization (Weissleder and  
Pittet, 2008).  
Using innovative nano-carriers, we studied their elimination route and biodistribution features  
after PEGylation of their surface. Nano-carriers should be accurately targeted to obtain an  
acceptable biodistribution without accumulating in vital organs. The biodistribution depends  
on several physicochemical properties of the nano-carriers such as their size, but also the  
electrostatic charge and chemical composition of their surface (Debbage and Jaschke, 2008).  
Since fluorescence optical imaging is an easy, immediate, and noninvasive method, this tool  
makes a major contribution to the development of new innovative antitumoral nano-carriers  
(Weissleder, 2002; Weissleder and Pittet, 2008).  
We can use fluorescent dyes that are excitable at wavelengths greater than or equal to 633 nm  
at least, in particular for animal investigations. Imaging in the NIR spectrum (650-900nm)  
maximizes tissue penetration in addition to minimizing the autofluorescence from nontargeted  
tissues (Weissleder, 2001; Weissleder and Ntziachristos, 2003). The signal-to-background 
ratio, for detecting optical imaging agents, equals or exceeds that which can be achieved with  
other molecular imaging modalities.  
One of the major drawbacks of optical imaging concerns its limited depth of investigation.  
Depending on the machine used, the emission signal was collected at a 15-cm depthat best  
(Frangioni, 2008). The development of 3D cameras allows whole-body noninvasive  
investigations on small animals such as mice and rats. At the clinical level, optical imaging  
could be used to facilitate the surgery using nanoparticle probes, for example as established  
here for lymph node detection using a surgical Fluobeam device, or for other applications  
(Frangioni, 2008; Jechart and Messmann, 2008).  
Optical imaging is a sensitive method: 2 pmol of fluorescent Cy5 could be detected in the  
mouse brain (V. Josserand, unpublished data), a good spatial resolution close to the millimeter  
in 3D and 0.01mm2 in 2D (Collier et al., 2007; Frangioni, 2008), anda very fast temporal  
resolution. For example, in 2D, a series of images can be taken with milliseconds of exposure  
time. It must be noted that a 3D acquisition of a 2-cm3 volume is slower and would require  
10-15 min.  
 
To conclude, optical imaging is an inexpensive, easy-to-use, and nonradiative tool able to  
provide rapid semi-qualitative (2D), quantitative (3D), and functional information from  
cellular to the several-centimeter scale.  
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Figure legends  
 
Fig. 1: Representation of the RAFT-RGD drug carrier. The disulfide bridge is represented by  
“S-S”. Here, the drug is the pro-apoptotic (KLAKLAK)-NH2peptide.  
 
Fig. 2: Schematic representation of functionalized nanoparticles for imaging and targeted  
therapies.  
 
Fig. 3: Optical imaging of intraperitoneal TS/A-pc-pGL3 tumor-bearing mice. The tumor  
cells were detected noninvasively using different modalities and the positive RAFT-RGD-  
Alexa700 molecule (Left) or the negative control molecule RAFT-RAD-Alexa700 (Right).  
Bioluminescence imaging, 5 min after luciferase injection allowed the detection and  
localization of the peritenoal nodules because the injected tumor cells are Luciferase positive.  
2D-fluorescence and 3D fluorescence imaging performed 3 h after intravenous injection of  
RAFT-RGD-Alexa700 and RAFT-RAD-Alexa700demonstrated that RAFT-RGD but not  
RAFT-RAD was targeting these nodules.  
 
Fig. 4: Confocal imaging of RAFT-RGD-X1 on live MvM3-expressing cells, HEK293-M3. From  
left to right: phase contrast and nucleus staining (blue), RAFT-RGD-Cy3 (green), KLA-Cy5  
(red), and FRET signal obtained from KLA linked to RAFT-RGD (dark red). The images  
were obtained at 30 min (upper panel) and 2 h (lower panel). Scale bar: 20 Mm.  
 
Fig. 5: Drug release. (A) IGROV-1 cellswere incubated with RAFT-RGD-X2 and observed  
by confocal microscopy (40x). Red signal corresponding to the drug release appeared 1 h  
after addition to the cell culture medium. As demonstrated by the mitochondria labeling 
(green signal), the KLA massively reached its target. (B) Similar results were obtained on  
three different cell types expressing the integrin αvβ3. Scale bar: 10 Mm.  
 
Fig. 6: (A)and (C)Fluorescence reflectance imaging of nudemice laid on the back (left) and  
the belly (right), 24 h after the intravenous injection of two different nanoparticles  
(representative examples, N = 4). (B)and (D)Corresponding biodistributionsof the different  
nano-carriers were obtained after sacrifice of the animals and exposure of the different organs  
directly under the camera.  
 
Fig. 7: Nanoparticles were subcutaneously injected in two locations in the vicinity of the  
tumor (pink dots). As observed after 15 min (A), 1 h (B) or 3 h (C), the nanoparticles were  
migrating toward two draining lymph nodes of the subcutaneous tumor, allowing their precise  
localization. (D) After resection, lymph nodes were observed under bright field and  
fluorescence imaging.  
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